Department of Orthopedics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Medicine (Baltimore). 2021 Apr 30;100(17):e25564. doi: 10.1097/MD.0000000000025564.
Osteosarcoma is one of the most common primary bone tumour in children and young patients, and the third most common among adults. Its main treatment option is currently based on neoadjuvant or adjuvant chemoradiotherapy along with the lesion's surgical resection. The current study's primary aim is to examine the clinical therapeutic impacts of combined methotrexate, along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma.
We will perform a comprehensive literature search in English database (PubMed, EMBASE, Cochran Library CINAHL, and PsycINFO) and Chinese database (Chinese National Knowledge Infrastructure, VIP information database, Chinese Biomedical Database, and WanFang Database) with no language restriction from their inception to the search date. Additionally, two independent authors will screen the works of literature obtained from these databases, obtain information, and examine the risks of data included for the studies' bias. Furthermore, we intend to employ the Q statistics as well as I2 statistics to calculate heterogeneity among each study's analysis. Accordingly, we will utilize the funnel plots and Egger test to assess the possibility of publication bias where relevant.
The current study aims to provide significant information regarding the clinical therapeutic impacts of combines methotrexate along with other chemotherapeutic agents to treat children and young adults suffering from osteosarcoma.
The present study will generate compelling evidence of combined methotrexate as well as other chemotherapeutic agents for osteosarcoma among children and young adults. Also, it will provide clinical practice suggestions.
The study is founded upon published data. Therefore, there is no requirement for ethics approval.
March 26, 2021.osf.io/a23rc. (https://osf.io/a23rc/).
骨肉瘤是儿童和青少年中最常见的原发性骨肿瘤之一，也是成年人中第三常见的原发性骨肿瘤。目前，其主要治疗方案是在新辅助或辅助化疗以及病变的手术切除的基础上进行。本研究的主要目的是研究联合使用甲氨蝶呤和其他化疗药物治疗骨肉瘤患儿和年轻成人的临床治疗效果。
我们将对英文数据库（PubMed、EMBASE、Cochrane 图书馆 CINAHL 和 PsycINFO）和中文数据库（中国国家知识基础设施、VIP 信息数据库、中国生物医学数据库和万方数据库）进行全面的文献检索，对这些数据库中从建库到检索日期的所有语言文献不设限制。此外，两名独立的作者将筛选从这些数据库中获得的文献工作，获取信息，并检查纳入研究的偏倚风险。此外，我们打算使用 Q 统计量和 I2 统计量来计算每个研究分析之间的异质性。因此，我们将在相关情况下使用漏斗图和 Egger 检验来评估发表偏倚的可能性。
本研究旨在提供关于联合使用甲氨蝶呤和其他化疗药物治疗骨肉瘤患儿和年轻成人的临床治疗效果的重要信息。
本研究将为儿童和年轻成人的骨肉瘤联合使用甲氨蝶呤和其他化疗药物提供有力的证据，并为临床实践提供建议。
本研究基于已发表的数据，因此不需要伦理批准。
OSF 注册号：2021 年 3 月 26 日，osf.io/a23rc（https://osf.io/a23rc/）。
